ProteoMediX: Prostate's PI3K biomarkers

ProteoMediX PI3K blood test seeks to avoid unneeded biopsies for prostate cancer

ProteoMedix AG is developing a multiplexed ELISA-based blood test that aims to confirm an initial PSA positive result and reduce unneeded biopsies by monitoring a quartet of biomarkers associated with alterations in PI3K signaling, a common underlying cause of prostate cancer. The company believes its ELISA could have an advantage over competing tests because it measures the activity of a tumor suppressor that has been directly linked to disease development.

While the effectiveness of PSA testing as a screening tool remains a topic of intense debate, there is widespread agreement that new diagnostics are

Read the full 930 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers